ArticleACS central science2020
Programmable Bivalent Peptide-DNA Locks for pH-Based Control of Antibody Activity.
Article in ACS central science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- MARPLE: A Proximity-Triggered CRISPR-Cas13 Platform for Ultrasensitive Antibody Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- pH-Responsive Triplex DNA Nanoswitches: Surface Plasmon Resonance Platform for Bladder Cancer-Associated microRNAs.ACS nano · 2025Article
- A Generic Antibody-Blocking Protein That Enables pH-Switchable Activation of Antibody Activity.ACS chemical biology · 2024Article
- Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics.Antibodies (Basel, Switzerland) · 2023Review
- Synthetic Antigen-Conjugated DNA Systems for Antibody Detection and Characterization.ACS sensors · 2023Review
- Recent and future perspectives on engineering interferons and other cytokines as therapeutics.Trends in biochemical sciences · 2023Review
- Applications of triplex DNA nanostructures in sensor development.Analytical and bioanalytical chemistry · 2022Review
- Switchable immune modulator for tumor-specific activation of anticancer immunity.Science advances · 2021Article
- Synergistic DNA- and Protein-Based Recognition Promote an RNA-Templated Bio-orthogonal Reaction.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control.ACS central science · 2021Review
- Supramolecular Nanoscaffolds within Cytomimetic Protocells as Signal Localization Hubs.Journal of the American Chemical Society · 2020Article
- A molecular device: A DNA molecular lock driven by the nicking enzymes.Computational and structural biotechnology journal · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to control antibody activity by pH has important applications in diagnostics, therapeutic antibody targeting, and antibody-guided imaging. Here, we report the rational design of bivalent peptide-DNA ligands that allow pH-dependent control of antibody activity. Our strategy uses a pH-responsive DNA triple helix to control switching from a tight-binding bivalent peptide-DNA lock into a weaker-binding monovalent ligand. Different designs are introduced that allow antibody activation at both basic and acidic pHs, either autonomously or in the presence of an additional oligonucleotide trigger. The pH of antibody activation could be precisely tuned by changing the DNA triple helix sequence. The peptide-DNA locks allowed pH-dependent antibody targeting of tumor cells both in bulk and for single cells confined in water-in-oil microdroplets. The latter approach enables high-throughput antibody-mediated detection of single tumor cells based on their distinctive metabolic activity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.